Please log in to view this page
Username
Password
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
